Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.98 |
| ▸ | AR | P10275 | 3/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61743 | 0.99 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL13579113 | 0.86 | PGR (0.77) | PGRARNR3C1NR3C2 | |
| SCHEMBL5524424 | 0.85 | PGR (0.76) | PGRARNR3C1NR3C2 | |
| Tanaproget SCHEMBL62188 | 0.85 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL7686696 | 0.84 | PGR (0.74) | PGRARNR3C1NR3C2 | |
| SCHEMBL1224081 | 0.84 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL5518269 | 0.84 | PGR (0.74) | PGRARNR3C1NR3C2 | |
| SCHEMBL5515556 | 0.83 | PGR (0.72) | PGRARNR3C1NR3C2 | |
| SCHEMBL5514404 | 0.83 | PGR (0.72) | PGRARNR3C1NR3C2 | |
| SCHEMBL5515576 | 0.83 | PGR (0.72) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609712-B2 | Purification of progesterone receptor modulators | WYETH LLC (US) | 2013-12-17 | — | — | US | claimed |
| US-20130012702-A1 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | WYETH LLC (US) | 2013-01-10 | — | — | US | claimed |
| US-8309594-B2 | Purification of progesterone receptor modulators | WYETH LLC (US) | 2012-11-13 | — | — | US | claimed |
| US-20090143577-A1 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-06-04 | — | — | US | claimed |
| US-20050250766-A1 | Purification of progesterone receptor modulators | WYETH (US) | 2005-11-10 | — | — | US | claimed |
| US-8609712-B2 | Purification of progesterone receptor modulators | WYETH LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130012702-A1 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | WYETH LLC (US) | 2013-01-10 | — | — | US | disclosed |
| US-8309594-B2 | Purification of progesterone receptor modulators | WYETH LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-7514466-B2 | Purification of progesterone receptor modulators | WYETH (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756072-A2 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | Wyeth (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005104711-A2 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250766-A1 | Purification of progesterone receptor modulators | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012702-A1 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC1, GNRHR | PGR 1/4885AR 21/4885NR3C1 31/4885 |
| US-20090143577-A1 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC1, GNRHR | PGR 1/4885AR 21/4885NR3C1 31/4885 |
| US-20050250766-A1 | Purification of progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | PGR 1/4885AR 22/4885NR3C1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.